Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: July 2014

New Melanoma Data at ASCO 2014 – Insight into Clinical Impact

Today MDoutlook releases its third and final OncoPoll™ focusing on Melanoma. Exciting new data was presented at ASCO 2014, especially in the new area of immuno-oncology therapies.

Your complimentary report concludes that:

  • Survey participants averaged 45 cases of melanoma each in the last 3 months
  • Considering both clinical efficacy and potential adverse events, oncologists have given nivolumab + ipilimumab, nivolumab alone, and pembrolizumab very high ratings (>5 out of 7)
  • Nearly twice as many BRAF wild-type patients compared to BRAF V600E/K patients are expected to receive an immune checkpoint inhibitor targeting the PD-1/PD-1L axis in their 1st line of treatment
  • 93% of oncologists believe ipilimumab will be somewhat important to very important as an adjuvant treatment for stage III disease with improvements in RFS and OS
  • Majority of oncologists (68%) believe that, if gaining regulatory approval, T-VEC will only impact a minority of patients with unresectable melanoma

The MDoutlook Annual OncoPoll Series are held after the largest international meetings of cancer professionals to establish and communicate key learnings and areas of important change in the management of cancer. Close to 200 oncologists from 27 countries spanning 4 continents responded directly after ASCO, the largest annual meeting of cancer professionals in the world.

We very much appreciate everyone’s contribution and collaboration, and are committed to advance research and treatment of cancer through widespread communication of this insight. Cancer is a leading cause of death globally and fast becoming the #1 cause in the United States. The WHO expects annual cancer cases to grow from 14 million in 2012 to 22 million in the next two decades.

We thank our partners at Oncology Business Review for their support in sharing our research through their network.

MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Please contact us discuss how MDoutlook can answer your disease intelligence needs.

MDoutlook ASCO 2014 OncoPoll – CLL and Mantle Cell Lymphoma

Continuing the tradition of immediate insight into how new data presented at ASCO 2014 is impacting clinical practice worldwide, MDoutlook has released its second of three OncoPoll™ report from ASCO 2014, focusing on Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma.

  • CLL-treatment naïve is the largest proportion of lymphoma patients seen in clinical practices; Mantle cell lymphoma patients are the second most seen per quarter
  • Results of the RESONATE trial are not expected to increase the usage of Ibrutinib for CLL- treatment naïve, CLL-relapsed/refractory, Del 17p or Del 11q patients (±0.3-2.2% change), in comparison to usage in the last three months
  • The highest proportion of oncologists (39%) believe that GS-9973 will have a large impact to a minority of their relapsed/refractory CLL patients
  • Oncologists would expect to use VR-CAP in a higher proportion (42%) of their transplant-ineligible Mantle cell lymphoma patients in comparison to R-CHOP (36%)

Download your courtesy copy of the MDoutlook ASCO 2014 OncoPoll – CLL report by clicking on the link.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research with all our colleagues.

MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Please contact us discuss how MDoutlook can answer your disease intelligence needs.